LENSAR receives FDA clearance of ALLY Adaptive Cataract Treatment System


The FDA cleared LENSAR’s (NASDAQ:LNSR) next-generation ALLY Adaptive Cataract Treatment System to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery procedure seamlessly in a single, sterile environment. 

The company plans to deliver the first ALLY systems to surgeons in the third quarter of 2022 through a controlled and targeted initial launch. Following this launch, the company plans to make ALLY widely available to cataract surgeons in 2023.

“We are seeing an overwhelmingly positive response to the ALLY system,” Nick Curtis, CEO of LENSAR, said in a statement. 

“Over 125 surgeons have experienced ALLY firsthand, during demonstrations performed at the American Society of Cataract and Refractive Surgery Annual Meeting in April, and more recently at our home office,” he added.

ALLY is the first cataract surgery platform to provide adaptive intelligence to automatically determine cataract density, optimize fragmentation patterns, and energy settings, with the goal of minimizing overall energy delivered to complete the cataract procedure more efficiently and help contribute to quicker visual recovery, and better patient outcomes.